BridgeBio Pharma (BBIO) – Research Analysts’ Recent Ratings Updates

Several analysts have recently updated their ratings and price targets for BridgeBio Pharma (NASDAQ: BBIO):

• 10/27/2025 – BridgeBio Pharma was given a new $68.00 price target on by analysts at Leerink Partners. They now have an “outperform” rating on the stock.
• 10/27/2025 – BridgeBio Pharma had its “outperform” rating reaffirmed by analysts at Evercore ISI.
• 10/21/2025 – BridgeBio Pharma had its price target raised by analysts at Raymond James Financial, Inc. from $56.00 to $59.00. They now have an “outperform” rating on the stock.
• 10/8/2025 – BridgeBio Pharma had its “sell (d-)” rating reaffirmed by analysts at Weiss Ratings.
• 9/27/2025 – BridgeBio Pharma had its “sell (d-)” rating reaffirmed by analysts at Weiss Ratings.
• 9/15/2025 – BridgeBio Pharma had its “buy” rating reaffirmed by analysts at HC Wainwright. They now have a $70.00 price target on the stock.
• 9/12/2025 – BridgeBio Pharma had its price target raised by analysts at UBS Group AG from $72.00 to $82.00. They now have a “buy” rating on the stock.
• 9/3/2025 – BridgeBio Pharma had its price target raised by analysts at JPMorgan Chase & Co. from $55.00 to $70.00. They now have an “overweight” rating on the stock.
• 8/29/2025 – BridgeBio Pharma had its price target raised by analysts at HC Wainwright from $56.00 to $70.00. They now have a “buy” rating on the stock.

Insider Transactions at BridgeBio Pharma

In other news, CEO Neil Kumar sold 40,000 shares of the company’s stock in a transaction dated Wednesday, October 8th. The stock was sold at an average price of $54.78, for a total transaction of $2,191,200.00. Following the completion of the sale, the chief executive officer owned 855,686 shares in the company, valued at approximately $46,874,479.08. This represents a 4.47% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, CFO Thomas Trimarchi sold 42,237 shares of the business’s stock in a transaction dated Thursday, August 21st. The stock was sold at an average price of $49.48, for a total value of $2,089,886.76. Following the transaction, the chief financial officer directly owned 421,081 shares of the company’s stock, valued at $20,835,087.88. This represents a 9.12% decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 597,913 shares of company stock valued at $29,034,227. Corporate insiders own 18.20% of the company’s stock.

BridgeBio Pharma, Inc, a commercial-stage biopharmaceutical company, discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases and cancers. Its products in development programs include AG10, a next-generation oral small molecule near-complete TTR stabilizer that is in Phase 3 clinical trial for the treatment of TTR amyloidosis, or transthyretin amyloid cardiomyopathy (ATTR-CM); low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 double-blinded, placebo-controlled pivotal study for the treatment option for children with achondroplasia; and BBP-631, an AAV5 gene transfer product candidate that is in Phase 1/2 clinical trial for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD.